Evidence map›Paper›PMID 41553374›Full record

ArticleCancer chemotherapy and pharmacology2026

Mapping drug-drug interactions in pharmacokinetic boosting of olaparib.

Joanneke K Overbeek, Sarmad M S Naoom, Laura Nijboer, Haiko J Bloemendal, Petronella B Ottevanger, Nielka P van Erp, David M Burger, Rob Ter Heine

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer chemotherapy and pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Joanneke K OverbeekDepartment of Pharmacy, Pharmacology and Toxicology, Radboud university medical center, PO box 9101, Nijmegen, 6500HB, the Netherlands. j.k.overbeek@lumc.nl.ORCID http://orcid.org/0000-0002-8802-4124
Sarmad M S NaoomDepartment of Pharmacy, Pharmacology and Toxicology, Radboud university medical center, PO box 9101, Nijmegen, 6500HB, the Netherlands.
Laura NijboerDepartment of Pharmacy, Pharmacology and Toxicology, Radboud university medical center, PO box 9101, Nijmegen, 6500HB, the Netherlands.ORCID http://orcid.org/0009-0007-6745-5981
Haiko J BloemendalDepartment of Medical Oncology, Radboud university medical center, Nijmegen, Netherlands.ORCID http://orcid.org/0000-0002-8902-4337
Petronella B OttevangerDepartment of Medical Oncology, Radboud university medical center, Nijmegen, Netherlands.ORCID http://orcid.org/0000-0001-8209-487X
Nielka P van ErpDepartment of Pharmacy, Pharmacology and Toxicology, Radboud university medical center, PO box 9101, Nijmegen, 6500HB, the Netherlands.ORCID http://orcid.org/0000-0003-1553-178X
David M BurgerDepartment of Pharmacy, Pharmacology and Toxicology, Radboud university medical center, PO box 9101, Nijmegen, 6500HB, the Netherlands.ORCID http://orcid.org/0000-0001-7279-2818
Rob Ter HeineDepartment of Pharmacy, Pharmacology and Toxicology, Radboud university medical center, PO box 9101, Nijmegen, 6500HB, the Netherlands.

Funding

ZonMw 10140021910005
6 · The paper itself

Abstract

introductionIn pharmacokinetic (PK) boosting, an intentional drug-drug interaction (DDI) is used to increase the exposure of another drug. PK boosting of the anticancer drug olaparib with the potent Cytochrome P450 (CYP3A)-inhibitor cobicistat can improve oral bioavailability, tolerability, and affordability. Cancer patients often present with many comedications that can also be affected by CYP3A-inhibitors, which requires thorough assessment of DDIs. This may hamper the feasibility of boosting. Here, we report potential DDIs between cobicistat and comedication in a retrospective cohort of patients treated with olaparib and how these DDIs can be mitigated.

methodsPatients who received olaparib between April 2017 and February 2024 were included. Comedications at the start of olaparib treatment were screened for potential DDIs with cobicistat if PK boosting would have been initiated in these patients. Relevant DDIs were reviewed by an expert panel of pharmacists and clinical pharmacologists and recommendations for mitigating interventions were formulated.

resultsIn total, 97 patients were included with a median of six concomitant medications per patient (range 0-13). 59% of patients presented with at least one relevant DDI. With the recommended interventions, 14% of patients had a DDI that required additional monitoring and 1% had a contra-indicated DDI.

conclusionsDDIs were highly prevalent when PK boosting of olaparib is applied. Nonetheless, nearly all DDIs could be mitigated by an intervention and most interventions could be applied without additional monitoring. PK boosting of olaparib with cobicistat is thus considered feasible with appropriate expertise and resources.

Indexed as

Antineoplastic AgentsCobicistatCytochrome P-450 CYP3A InhibitorsNeoplasmsPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsAdultAgedAged, 80 and overDrug InteractionsFemaleHumansMaleMiddle AgedRetrospective StudiesAntineoplastic AgentsCobicistatCytochrome P-450 CYP3A InhibitorsolaparibPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsCobicistatDrug-drug interactionsOlaparibPharmacokinetic boosting

Identifiers

PMID41553374

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.